直接口服抗凝药与华法林在肥胖急性静脉血栓栓塞患者中的有效性与安全性
本研究为回顾性匹配队列研究,纳入1840例体重>100 kg且<300 kg的急性VTE住院患者,比较DOAC与华法林的有效性和安全性。结果显示两组12个月内VTE复发率、PE和DVT发生率及出血率均无显著差异,提示DOAC可作为肥胖急性VTE患者华法林的合理替代。
要点
- 肥胖急性VTE患者使用DOAC与华法林的12个月VTE复发率无显著差异(6.5% vs 6.4%)。
- DOAC组与华法林组的PE、DVT及出血发生率均无显著差异。
- DOAC可考虑作为肥胖急性VTE患者华法林的合理替代方案。
核心结论
- 在体重>100 kg且<300 kg的肥胖急性VTE患者中,DOAC与华法林在12个月内VTE复发、PE、DVT及出血方面无显著差异。
- DOAC应被视为肥胖急性VTE患者华法林的合理替代选择。
研究设计与样本
- 回顾性匹配队列研究,纳入40家学术、社区和专科医院整合医疗系统。
- 共1840例成人急性VTE住院患者,DOAC组632例(阿哌沙班、达比加群或利伐沙班),华法林组1208例。
- 华法林组按2:1比例与DOAC组匹配,匹配因素包括VTE病史、慢性肾病、种族和年龄。
主要发现
- DOAC组与华法林组12个月内VTE复发率分别为6.5%和6.4%(p=0.93)。
- PE发生率分别为3.7%和3.8%(p=0.94),DVT发生率分别为3%和3.5%(p=0.56)。
- 出血发生率分别为1.7%和1.2%(p=0.31)。
临床怎么用
- 对于体重>100 kg且<300 kg的肥胖急性VTE患者,可考虑使用DOAC作为华法林的替代。
- 临床决策时需结合患者具体情况,并注意当前指南对体重>120 kg或BMI>40 kg/m2患者使用DOAC的限制。
局限性
- 回顾性研究设计可能存在残余混杂。
- 研究人群限于体重>100 kg且<300 kg,未涵盖体重>120 kg或BMI>40 kg/m2的特定亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Studies on the use of direct oral anticoagulants (DOACs) in obese patients are limited. Current guidelines advise against DOAC use in patients with a body weight more than 120 kg or body mass index higher than 40 kg/m2 . Therefore, the aim of this study was to evaluate the effectiveness and safety of DOACs versus warfarin for the treatment of acute venous thromboembolism (VTE) in obese patients. DESIGN: Retrospective matched cohort study. SETTING: Integrated delivery system of 40 academic, community, and specialty hospitals. PATIENTS: A total of 1840 adults with a primary admission diagnosis of acute VTE who received a DOAC (apixaban, dabigatran, or rivaroxaban [632 patients] or warfarin [1208 patients]) while hospitalized between January 1, 2011, and October 1, 2015, and who had a body weight more than 100 kg and less than 300 kg, were included. Patients in the warfarin group were matched in a 2:1 ratio to patients who received a DOAC based on history of VTE, chronic kidney disease, race, and age. MEASUREMENTS AND MAIN RESULTS: The primary outcome was recurrence of VTE within 12 months of the index admission date. Secondary outcomes included occurrence of pulmonary embolism (PE) and deep vein thrombosis (DVT) events separately within the study time frame, as well as bleeding within 12 months of the index admission date. No significant difference in the recurrence of VTE was observed between patients who received a DOAC compared with those who received warfarin (6.5% vs 6.4%, p=0.93). Likewise, no significant differences in the occurrence of PE and DVT were seen between the DOAC- and warfarin-treated patients (3.7% vs 3.8%, p=0.94, and 3% vs 3.5%, p=0.56, respectively). Bleeding occurred in 1.7% and 1.2% of patients in the DOAC and warfarin groups, respectively (p=0.31). CONCLUSION: To our knowledge, this is the largest clinical study to date showing that patients with obesity can be treated effectively and safely with a DOAC compared with warfarin for acute VTE. Thus DOACs should be considered a reasonable alternative to warfarin for treatment of acute VTE in obese patients.
引用
- Coons JC, Albert L, Bejjani A, et al. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. Pharmacotherapy. 2020. PMID: 31968126. doi:10.1002/phar.2369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。